logo
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Yahoo09-07-2025
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.
Cogent intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib as well as for working capital and general corporate purposes.
J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering.
The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission (SEC) on February 10, 2023 and automatically became effective upon filing.
A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering were filed with the SEC on July 8, 2025. A final prospectus supplement and the accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained at the SEC's website at www.sec.gov, or by request to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorgan.com and postsalemanualrequests@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors, a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the completion of the public offering and the use of proceeds therefrom, are forward-looking statements. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to our capital position and the sufficiency of our capital to fund our operations in future periods; our use of the net proceeds of the underwritten public offering; risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the underwritten public offering; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in our filings with the SEC, including our Registration Statement on Form S-3ASR, which was filed with the SEC on February 10, 2023 and automatically became effective upon filing, as may be amended from time to time, together with the accompanying base prospectus contained therein and the documents incorporated by reference therein, including our most recent Annual Report on Form 10-K, our Quarterly Report on Form 10-Q and our subsequent periodic reports filed with the SEC, and the preliminary prospectus supplement related to this offering. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
Contact:
Christi WaarichSenior Director, Investor Relationschristi.waarich@cogentbio.com617-830-1653
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abacus Global Management Announces Successful Completion of Exchange Offer and Consent Solicitation
Abacus Global Management Announces Successful Completion of Exchange Offer and Consent Solicitation

Yahoo

time26 minutes ago

  • Yahoo

Abacus Global Management Announces Successful Completion of Exchange Offer and Consent Solicitation

ORLANDO, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. ('Abacus' or the 'Company') (NASDAQ: ABL), a leader in the alternative asset management space, today announced the completion of its previously announced exchange offer (the 'Offer') and consent solicitation (the 'Consent Solicitation') relating to its (i) outstanding public warrants (the 'public warrants') and (ii) outstanding private placement warrants (the 'private placement warrants' and, together with the public warrants, the 'warrants') to purchase shares of common stock, par value $0.0001 per share, of the Company ('common stock'). The Company's common stock and public warrants are listed on the Nasdaq Capital Market (the 'Nasdaq') under the symbols 'ABL' and 'ABLLW,' respectively. The Company issued 4,183,160 shares of common stock in exchange for the warrants tendered in the Offer. On July 30, 2025, the Company and Continental Stock Transfer & Trust Company entered into the related amendment to the warrant agreement governing the warrants (the 'Warrant Amendment'). Pursuant to the Warrant Amendment, the Company has exercised its right to exchange each warrant that is outstanding upon the closing of the Offer for 0.207 shares of common stock per warrant, which is a ratio 10% less than the exchange ratio applicable to the Offer (the 'Post-Offer Exchange'). The Company has fixed the date for the Post-Offer Exchange as August 14, 2025. As a result of the completion of the Offer and the Post-Offer Exchange, no warrants will remain outstanding. Accordingly, the public warrants are expected to be suspended from trading on the Nasdaq as of the close of business on August 14, 2025, and will be delisted. The shares of common stock will continue to be listed and trade on the Nasdaq under the symbol 'ABL.' Following completion of the Offer, there are approximately 102,050,981 shares of common stock outstanding (an increase of approximately 4% from prior to the closing of the Offer), and following completion of the Post-Offer Exchange there will be approximately 102,555,154 shares of common stock outstanding (an increase of approximately 5% from prior to the closing of the Offer and the Post-Offer Exchange). The Company engaged SG Americas Securities, LLC as the dealer manager for the Offer and Consent Solicitation, D.F. King & Co., Inc. as the information agent for the Offer and Consent Solicitation, and Continental Stock Transfer & Trust Company served as the exchange agent for the Offer and Consent Solicitation. About Abacus Abacus Global Management (NASDAQ: ABL) is a leading financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. With a focus on longevity-based assets and personalized financial planning, Abacus leverages proprietary data analytics and decades of industry expertise to deliver innovative solutions that optimize financial outcomes for individuals and institutions worldwide. Contacts: Investor RelationsRobert F. Phillips – SVP Investor Relations and Corporate Affairs rob@ 290-1198 David Jackson – Managing Director of Investor Relations david@ 299-0716 Abacus Global Management Public Relationspress@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Can Roku's Q2 Ad Gains and Cost Cuts Rekindle Investor Faith?
Can Roku's Q2 Ad Gains and Cost Cuts Rekindle Investor Faith?

Yahoo

time26 minutes ago

  • Yahoo

Can Roku's Q2 Ad Gains and Cost Cuts Rekindle Investor Faith?

Roku Inc. (NASDAQ:ROKU) will report second-quarter earnings after the close on Thursday, July 31. Analysts expect a loss of $0.15 per share on $1.071 billion in revenue, reflecting modest top-line growth but a 40% improve on the bottom-line, as the company works to reaccelerate its ad platform and operational scalability. Shares are up 21% year-to-date but still down more than 80% from its all-time high of $490.76 set on July 27, 2021. Investors will watch closely for signs that platform revenue is recovering after a sluggish 2023. Key metrics will include average revenue per user (ARPU), total streaming hours, and account growth. Roku's high-margin platform business is expected to offset hardware losses, but bulls want to see evidence of improving monetization and a clearer path to EBITDA breakeven. Any commentary on licensing deals for the Roku OS or international expansion could also be well received. Cost discipline will remain in focus. After multiple rounds of layoffs and ad-tech consolidation, Roku has narrowed its losses and guided toward positive adjusted EBITDA by year-end. Investors will also be looking for any updates on AI integration across its ad targeting stack, as peers invest heavily in data-driven automation. While the stock has rebounded, sentiment remains fragile, and execution on margins may matter more than headline growth this quarter. This article first appeared on GuruFocus. Sign in to access your portfolio

T. Rowe Q2 Earnings Preview: Can Market Gains Finally Stop the Bleeding?
T. Rowe Q2 Earnings Preview: Can Market Gains Finally Stop the Bleeding?

Yahoo

time26 minutes ago

  • Yahoo

T. Rowe Q2 Earnings Preview: Can Market Gains Finally Stop the Bleeding?

T. Rowe Price Group Inc. (NASDAQ:TROW) will report second-quarter earnings before the market opens on Friday, August 1. Analysts expect EPS of $2.15 on $1.728 billion in revenue, representing flat growth as market-driven AUM recovery offsets continued pressure on flows. The stock has lagged year-to-date, weighed down by tepid organic growth, cost control efforts, and ongoing concerns over the competitiveness of active strategies. Key metrics will include total AUM, organic net flows, and average fee rate trends. While the S&P 500 and other major benchmarks posted strong gains in Q2, investor sentiment remains cautious over whether T. Rowe can convert market beta into net inflows. T. Rowe reported net outflows of $8.6 billion in Q1 2025, marking its sixteenth consecutive quarter of redemptions, meaning even a modest inflow this quarter would represent a meaningful break in trend and could help shift sentiment. Expense discipline will also be in focus as management seeks to protect margins without compromising strategic investments, particularly in retirement solutions and model portfolios. With shares still more than 50% below their all-time high, bulls are watching for signs that heightened volatility, recent market strength, and renewed interest in active management can lift both earnings and sentiment. But without clearer evidence of flow stabilization or traction in new products, the upside may remain capped. This article first appeared on GuruFocus.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store